Subcutaneous Administration of Frexalimab In Relapsing Multiple Sclerosis and Non-Relapsing Secondary Progressive Multiple Sclerosis: Design of the phase 3 Frexcite Trial (CMSC 2026) - Jun 2, 2026 - Abstract #DMT57; Pres time: May 28, 2026; 05:00 PM - 07:00 PM; Location: Exhibit Hall B (Charlotte Convention Center); P2, P3 | "This FREXCITE Phase 3 bridging study will assess the PK non-inferiority, safety, efficacy, and patient experience of frexalimab administered SC using OBDS compared to IV administration in participants with RMS and nrSPMS, supporting a more convenient route of administration for those requiring long-term frexalimab therapy."
P3 data • CNS Disorders • Multiple Sclerosis • CD40LG
|
|
Tanuja Chitnis , MD, FAAN; Christine Farenc , PhD, PharmD; Gavin Giovannoni , MBBCh, PhD; Cristina Granziera , MD, PhD; Eva Kubala Havrdova , MD, PhD; Stephen Krieger , MD; Yang Mao-Draayer , MD, PhD; Xavier Montalban , MD, PhD, FEAN, FAAN, FCAHS; Stephane Saubadu , MD; Philippe Truffinet , MD; Patrick Vermersch , MD,PhD; Heinz Wiendl , MD
|